The National Institutes of Health (NIH) is seeking proposals for the development of wearable technologies aimed at facilitating the remote monitoring of cancer patients following treatment. The objective is to create integrated solutions that combine wearable sensors and advanced analytical tools to enable healthcare providers to monitor patients in real-time, thereby improving patient care and expanding access to clinical trials, particularly for underserved populations. This initiative is critical as it leverages advancements in wearable technology and machine learning to address treatment-related adverse events, enhancing the overall management of cancer care. Interested applicants can submit their proposals until October 18, 2024, with funding amounts of up to $400,000 for Phase I (12 months) and up to $2,250,000 for Phase II (2 years) available for selected projects. For more details, visit the solicitation link at [SBIR.gov](https://www.sbir.gov/topics/11148).

Fast-Track proposals will NOT be accepted. Direct-to-Phase II proposals will be accepted. Number of anticipated awards: 3-5 Budget (total costs, per award): Phase I: up to $400,000 for up to 12 months Phase II: up to $2,250,000 for up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Summary The growing sophistication of wearable device technologies coupled with recent advancements in machine learning, and other complex informatics approaches for biometric data analysis, have created new opportunities to develop tools capable of supporting clinical management of cancer patients during treatment. The goal of this contract topic is to accelerate the combination of wearable sensors, and other remote monitoring technologies, with sophisticated analytical approaches and user interfaces that allow patients to be remotely monitored for cancer- or treatment-related adverse events (e.g., acute chemotherapy-induced toxicities). Such technologies would offer complete solutions (e.g., hardware and software) to allow healthcare providers the ability to monitor a patient in real-time and preemptively mitigate adverse events when needed. A clear opportunity exists to substantially improve patient care and expand the footprint of clinical trials (decentralized) to more patients (e.g., medically underserved, rural, and more).

Topic

Agency

Program

Topic Link

Additional Information